|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Fondaparinux#Adult Indications and Dosage]] |
|
| |
|
| | | [[Category: Cardiovascular Drugs]] |
| '''Fondaparinux sodium''' (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to [[pulmonary embolism]]:
| | [[Category: Drug]] |
| | | [[Category: Anticoagulants]] |
| * in patients undergoing [[hip fracture]] surgery, including extended prophylaxis;
| |
| * in patients undergoing [[hip replacement]] surgery;
| |
| * in patients undergoing [[knee replacement]] surgery;
| |
| * in patients undergoing [[abdominal surgery]] who are at risk for thromboembolic complications.
| |
| | |
| Fondaparinux sodium (Arixtra) Injection is indicated for:
| |
| | |
| * the treatment of acute [[deep vein thrombosis]] when administered in conjunction with warfarin sodium, and
| |
| * the treatment of acute [[pulmonary embolism]] when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.
| |
| | |
| | |
| | |
| | |
| {{FDA}}
| |
| | |
| | |
| | |
| [[Category:Drugs]] | |